Zenas BioPharma (ZBIO) EBIT Margin (2023 - 2026)

Zenas BioPharma (ZBIO) posted quarterly EBIT Margin of 373.3% for Q1 2025, up 66.44% quarter-over-quarter from 1112.46% in Q4 2024.

Zenas BioPharma (ZBIO) EBIT Margin (2023 - 2026) Analysis & Trends

Zenas BioPharma's EBIT Margin history runs 3 years deep, the most recent figure standing at 373.3% for Q1 2025.

In Q1 2025, EBIT Margin changed N/A year-over-year to 373.3%; the TTM figure through Dec 2025 stood at 3830.57% (down 55283.0% YoY), while the FY2025 annual figure was 3830.57%, down 55281.0% from the prior year.
EBIT Margin for Q1 2025 stood at 373.3%, up from 1112.46% in the prior quarter.
The five-year high for EBIT Margin was 71.25% in Q3 2023, with the low at 1112.46% in Q4 2024.
The 3-year median for EBIT Margin is 373.3% (2025), against an average of 471.5%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-105.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-	-10,765.90%

Download Data